AAM
CORT icon

Advisors Asset Management’s Corcept Therapeutics CORT Stock Holding History

Advisors Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$569K Sell
6,545
-3,573
-35% -$216K 0.01% 958
2026
Q1 		$408K Sell
10,118
-1,908
-16% -$71.3K 0.01% 1010
2025
Q4 		$419K Sell
12,026
-5,189
-30% -$408K 0.01% 1001
2025
Q3 		$1.43M Sell
17,215
-1,720
-9% -$124K 0.02% 695
2025
Q2 		$1.39M Buy
18,935
+237
+1% +$17.2K 0.02% 672
2025
Q1 		$2.14M Buy
18,698
+2,607
+16% +$159K 0.04% 542
2024
Q4 		$811K Buy
16,091
+3,430
+27% +$180K 0.01% 798
2024
Q3 		$586K Buy
12,661
+2,897
+30% +$103K 0.01% 891
2024
Q2 		$317K Buy
9,764
+4,177
+75% +$114K 0.01% 1008
2024
Q1 		$141K Buy
5,587
+5,055
+950% +$119K ﹤0.01% 1185
2023
Q4 		$17.3K Buy
+532
New +$14.6K ﹤0.01% 1363

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisors Asset Management's CORT Position: Q2 2026 in Review

Advisors Asset Management reduced its Corcept Therapeutics (CORT) stake by 35% in Q2 2026, selling an estimated $216K and leaving 6,545 shares worth $569K. The position accounts for 0.01% of the portfolio, ranked #958.

Advisors Asset Management first reported a position in CORT in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.14M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Advisors Asset Management held 6,545 shares of Corcept Therapeutics worth $569K as of Q2 2026.
  • Advisors Asset Management sold 3,573 Corcept Therapeutics shares in Q2 2026, an estimated $216K.
  • Corcept Therapeutics made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #958 holding.
  • Advisors Asset Management first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Advisors Asset Management's Corcept Therapeutics position peaked at $2.14M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.